| 3.08 -2.89 (-48.41%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.09 |
1-year : | 10.89 |
| Resists | First : | 6.92 |
Second : | 9.32 |
| Pivot price | 5.1 |
|||
| Supports | First : | 3.03 |
Second : | 2.52 |
| MAs | MA(5) : | 4.43 |
MA(20) : | 5.84 |
| MA(100) : | 9.91 |
MA(250) : | 12.27 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.4  |
| %K %D | K(14,3) : | 21.8 |
D(3) : | 19.8 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 49.79 | Low : | 2.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IXHL ] has closed above bottom band by 20.4%. Bollinger Bands are 94.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.47 - 6.5 | 6.5 - 6.52 |
| Low: | 5.03 - 5.05 | 5.05 - 5.08 |
| Close: | 5.93 - 5.97 | 5.97 - 6.01 |
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Thu, 12 Mar 2026
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment - Benzinga
Thu, 12 Mar 2026
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes - Bitget
Thu, 12 Mar 2026
Incannex announces enhanced development strategy for IHL-42X - TipRanks
Thu, 12 Mar 2026
Incannex Healthcare Inc Shares Drop 20% After $10 Million Placement Announcement - Intellectia AI
Thu, 12 Mar 2026
Incannex Highlights Enhanced Phase 2 Study and Updates - TipRanks
Thu, 12 Mar 2026
Incannex Healthcare Announces $10 Million Direct Offering - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 3.3 (%) |
| Shares Short | 727 (K) |
| Shares Short P.Month | 557 (K) |
| EPS | -22.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37 % |
| Return on Equity (ttm) | -130.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|